Dendreon Starts Trial of Cancer Pill

Xconomy Seattle — 

Dendreon, the Seattle company developing an immune-stimulating therapy for prostate cancer, said today it has started a clinical trial of a cancer drug made in a more conventional pill form. The company will examine safety of D3263 at a variety of doses in patients with solid tumors. Dendreon has been advancing this program toward clinical trials to diversify its pipeline beyond Provenge, its lead drug candidate, which succeeded in a clinical trial earlier this month.